Drug combination shows better tolerance and effectiveness in metastatic renal cell cancer

(Dartmouth-Hitchcock Medical Center) A novel combination of nivolumab plus ipilimumab for patients with metastatic kidney cancer is proving to be a more effective treatment with more durable tumor response than the two immunotherapies used separately. The promising combination therapy demonstrated manageable safety, notable antitumor activity, and durable responses with better long term overall survival in patients with metastatic renal cell cancer.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news